Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
Objective. To evaluate the efficacy of autologous cytokine-induced killer (CIK) cells in patients with renal cell carcinoma (RCC). Methods. 20 patients diagnosed with TNM stage I or II RCC were randomly divided into two groups, a CIK cell treatment group and a control group. The endpoint was progres...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/195691 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564013149454336 |
|---|---|
| author | Yajing Zhang Jin Wang Yao Wang Xue-Chun Lu Hui Fan Yang Liu Yan Zhang Kai-Chao Feng Wen-Ying Zhang Mei-Xia Chen Xiaobing Fu Wei-Dong Han |
| author_facet | Yajing Zhang Jin Wang Yao Wang Xue-Chun Lu Hui Fan Yang Liu Yan Zhang Kai-Chao Feng Wen-Ying Zhang Mei-Xia Chen Xiaobing Fu Wei-Dong Han |
| author_sort | Yajing Zhang |
| collection | DOAJ |
| description | Objective. To evaluate the efficacy of autologous cytokine-induced killer (CIK) cells in patients with renal cell carcinoma (RCC). Methods. 20 patients diagnosed with TNM stage I or II RCC were randomly divided into two groups, a CIK cell treatment group and a control group. The endpoint was progression-free survival (PFS) evaluated by Kaplan-Meier analyses. Results. CD3+, CD3+/CD8+, CD3+/CD4+, and CD3+/CD56+ levels increased after CIK cell culture (P<0.01). The median PFS in CIK cell treatment group was significantly longer than that in control group (PFS, 32.2 months versus 21.6 months; log-rank, P=0.032), all patients were alive during the course of followup, and there are no statistically significant differences between two groups in OS (log-rank, P=0.214). Grade III or greater adverse events were not observed. Conclusions. CIK cells treatment could prolong survival in patients with RCC after radical nephrectomy and showed acceptable curative effect with potential enhancement of cellular immune function. This trial is registered with Clinicaltrials.gov NCT01799083. |
| format | Article |
| id | doaj-art-c5114c50cb394e159ac97f7ec1838008 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-c5114c50cb394e159ac97f7ec18380082025-02-03T01:12:03ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/195691195691Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical NephrectomyYajing Zhang0Jin Wang1Yao Wang2Xue-Chun Lu3Hui Fan4Yang Liu5Yan Zhang6Kai-Chao Feng7Wen-Ying Zhang8Mei-Xia Chen9Xiaobing Fu10Wei-Dong Han11Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Cadre Health Care, Naval General Hospital, Beijing 100048, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaBiotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, ChinaObjective. To evaluate the efficacy of autologous cytokine-induced killer (CIK) cells in patients with renal cell carcinoma (RCC). Methods. 20 patients diagnosed with TNM stage I or II RCC were randomly divided into two groups, a CIK cell treatment group and a control group. The endpoint was progression-free survival (PFS) evaluated by Kaplan-Meier analyses. Results. CD3+, CD3+/CD8+, CD3+/CD4+, and CD3+/CD56+ levels increased after CIK cell culture (P<0.01). The median PFS in CIK cell treatment group was significantly longer than that in control group (PFS, 32.2 months versus 21.6 months; log-rank, P=0.032), all patients were alive during the course of followup, and there are no statistically significant differences between two groups in OS (log-rank, P=0.214). Grade III or greater adverse events were not observed. Conclusions. CIK cells treatment could prolong survival in patients with RCC after radical nephrectomy and showed acceptable curative effect with potential enhancement of cellular immune function. This trial is registered with Clinicaltrials.gov NCT01799083.http://dx.doi.org/10.1155/2013/195691 |
| spellingShingle | Yajing Zhang Jin Wang Yao Wang Xue-Chun Lu Hui Fan Yang Liu Yan Zhang Kai-Chao Feng Wen-Ying Zhang Mei-Xia Chen Xiaobing Fu Wei-Dong Han Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy Clinical and Developmental Immunology |
| title | Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy |
| title_full | Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy |
| title_fullStr | Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy |
| title_full_unstemmed | Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy |
| title_short | Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy |
| title_sort | autologous cik cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy |
| url | http://dx.doi.org/10.1155/2013/195691 |
| work_keys_str_mv | AT yajingzhang autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT jinwang autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT yaowang autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT xuechunlu autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT huifan autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT yangliu autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT yanzhang autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT kaichaofeng autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT wenyingzhang autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT meixiachen autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT xiaobingfu autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy AT weidonghan autologouscikcellimmunotherapyinpatientswithrenalcellcarcinomaafterradicalnephrectomy |